TD Cowen analyst Ryan Langston has maintained a Hold rating on Centene (NYSE: CNC) and raised the price target to $65 from $47. This adjustment reflects a revised valuation outlook for the healthcare company.

Rating and Target Details

The research note highlights the firm's updated stance on Centene's stock performance potential. Below is a summary of the revised metrics:

The Hold rating suggests that the stock is expected to perform in line with the broader market or sector average over the specified period.

Centene Corporation will release its 2026 second quarter financial results at approximately 6:00 a.m. ET on Tuesday, July 28, 2026. The company will host a conference call at 8:30 a.m. ET to review the results, providing investors with an opportunity to assess the healthcare enterprise's performance for the quarter.

Investors and interested parties can listen to the conference call by dialing 1-877-883-0383 (toll free) in the U.S. and Canada, or +1-412-902-6506 (toll) from abroad. The Elite Entry Number to expedite caller registration is 4306002. Alternatively, a live audio webcast will be available on the company's website under the Investors section.

A webcast replay will be available for on-demand listening shortly after the call concludes. The replay will be accessible for the next 12 months or until 11:59 p.m. ET on Tuesday, July 27, 2027. Additionally, a digital audio playback will be available until 9 a.m. ET on Tuesday, August 4, 2026, by dialing 1-855-669-9658 (toll free) in North America or +1-412-317-0088 (toll) from abroad, using access code 6500508.

Conference Call Details

Centene Corporation, a Fortune 500 company, provides integrated healthcare services to government-sponsored and commercial programs. The company focuses on under-insured and uninsured individuals, offering products to Medicaid and Medicare members, as well as those served by the Health Insurance Marketplace.